


# Discover & Deliver: The Sorrento Antibody Cocktail

**174** treatments and vaccines  
in the clinical stages of development




Right now, there are [174 COVID-19 treatments and vaccines in the clinical stages of development](#), not to mention 81 additional therapies in the pre-clinical stage. The world is holding its breath for the data.



Already, early results are showing promise. And this week, a small San Diego biopharmaceutical company, Sorrento Therapeutics, [released new laboratory evidence](#) that could move the needle from promise to product.

Sorrento claims to have discovered a unique COVID-19 antibody – a blood protein the body makes in response to and in defense against a specific antigen – that can create “100% inhibition” of COVID-19. **In other words, the unique antibody has so far been 100% effective in blocking COVID-19 from infecting healthy cells within just four days.**



Sorrento, [in partnership with Mount Sinai](#), is working to develop an antibody cocktail containing the unique antibody and other antibodies that they hope will prevent new COVID-19 infections. While the cocktail still needs to be tested in animal and human clinical trials, the initial laboratory performance has been positive.

According to [Sorrento CEO Dr. Henry Ji](#), “Our [...] antibody shows exceptional therapeutic potential and could potentially save lives.”

While the world awaits the discovery of a vaccine, the antibody cocktail could temporarily protect individuals from contracting COVID-19, which will be critical to getting America safely back to work.

We hope to see that potential realized soon.

—Jonathan Weinberger, Executive Vice President, Global Innovation Policy Center